List view / Grid view
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
A new study by Scripps Research reveals that apremilast, an FDA-approved anti-inflammatory drug, may help reduce both alcohol consumption and pain sensitivity, offering a potential dual therapy for alcohol use disorder.
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
A new UCLA study reveals that DNA mismatch repair genes play a crucial role in Huntington’s disease by driving neuronal damage and motor impairments. Targeting these genes, especially Msh3 and Pms1, could offer promising therapeutic avenues for the disease.
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
US researchers uncover that body building supplement: HMB, may help stop the progression of Alzheimer’s disease.
According to Swedish study, muscle fibres found in extraocular muscles seem to be resistant and even increase in proportion in those with ALS. This offers new treatment avenues for slowing down the disease.
US researchers uncover that certain nerve cells that have the capacity to regrow, are necessary for axon regeneration, providing hope for conditions like blindness and paralysis.
